Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$119.09 USD

119.09
1,584,539

-1.05 (-0.87%)

Updated Aug 14, 2025 12:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (146 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.

Zacks Equity Research

PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y

by Zacks Equity Research

PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues

Zacks Equity Research

Intrexon (XON) Reports In-Line Q1 Loss, Misses on Revenues

by Zacks Equity Research

Intrexon (XON) reports in line loss in the first quarter of 2019. Also, sales miss estimates.

Zacks Equity Research

Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

by Zacks Equity Research

Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.

Zacks Equity Research

Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1

by Zacks Equity Research

Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.

Zacks Equity Research

Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y

by Zacks Equity Research

Nektar's (NKTR) earnings and sales beat estimates in the first quarter. The company is progressing well with its pipeline candidates.

Zacks Equity Research

Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Intercept's (ICPT) Q1 revenues top estimates on strong Ocaliva sales, driven by sales force expansion.

Zacks Equity Research

Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (GILD) Outperforming Other Medical Stocks This Year?

Sweta Jaiswal, FRM headshot

Biotech ETFs in Focus on String of Q1 Earnings Beats

by Sweta Jaiswal, FRM

Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.

Zacks Equity Research

Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Novo Nordisk's (NVO) earnings and sales miss estimates in the first quarter of 2019.

Zacks Equity Research

Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1

by Zacks Equity Research

Biotech bigwig Gilead's (GILD) Q1 financial report is mixed with dismal sales and an earnings beat.

Zacks Equity Research

Gilead Sciences (GILD) Q1 Earnings Top Estimates

by Zacks Equity Research

Gilead (GILD) delivered earnings and revenue surprises of 8.64% and -0.49%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q1 results on May 7.

Zacks Equity Research

What's in the Cards for Novavax (NVAX) This Earnings Season?

by Zacks Equity Research

Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.

Zacks Equity Research

What's in the Cards for Sunesis (SNSS) This Earnings Season?

by Zacks Equity Research

Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.

Zacks Equity Research

AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?

by Zacks Equity Research

During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.

Zacks Equity Research

Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y

by Zacks Equity Research

While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.

Zacks Equity Research

What's in the Cards for Zynerba (ZYNE) This Earnings Season?

by Zacks Equity Research

Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.

Zacks Equity Research

What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.

Zacks Equity Research

What's in the Cards for Bausch Health (BHC) Q1 Earnings?

by Zacks Equity Research

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.

Zacks Equity Research

Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings?

by Zacks Equity Research

Incyte (INCY) is slated to report first-quarter results on Apr 30. Investors will primarily focus on Jakafi sales and pipeline updates.

Zacks Equity Research

What's in the Cards for Sarepta (SRPT) This Earnings Season?

by Zacks Equity Research

Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive first-quarter sales.

Zacks Equity Research

Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock?

by Zacks Equity Research

For Sangamo's (SGMO) Q1, investor focus will be on its gene therapy candidate, SB-525, currently under evaluation for hemophilia A. The company also boasts several other early-stage promising candidates in its pipeline.

Zacks Equity Research

Fibrocell (FCSC) Q1 Earnings: What's in Store for the Stock?

by Zacks Equity Research

For Fibrocell's (FCSC) Q1, investors will eye the company's progress with its gene therapy candidate, FCX-007, currently being developed for treating recessive dystrophic epidermolysis bullosa.

Zacks Equity Research

5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates

by Zacks Equity Research

So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.